Cancer research is not correlated with driver gene mutation burdens.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-07-12 Epub Date: 2024-06-21 DOI:10.1016/j.medj.2024.05.013

Gaurav Mendiratta, David Liarakos, Melinda Tong, Satoko Ito, Eugene Ke, George Goshua, Edward C Stites

{"title":"Cancer research is not correlated with driver gene mutation burdens.","authors":"Gaurav Mendiratta, David Liarakos, Melinda Tong, Satoko Ito, Eugene Ke, George Goshua, Edward C Stites","doi":"10.1016/j.medj.2024.05.013","DOIUrl":null,"url":null,"abstract":"Background: Cancer research is pursued with the goal of positively impacting patients with cancer. Decisions regarding how to allocate research funds reflect a complex balancing of priorities and factors. Even though these are subjective decisions, they should be made with consideration of all available objective facts. An accurate estimate of the affected cancer patient population by mutation is one variable that has only recently become available to inform funding decisions.Methods: We compared the overall incident burden of mutations within each cancer-associated gene with two measures of cancer research efforts: research grant funding amounts and numbers of academic manuscripts. We ask to what degree the aggregate set of cancer research efforts reflects the relative burdens of the different cancer genetic drivers. We thoroughly investigate the design of our queries to ensure that the presented results are robust and conclusions are well justified.Findings: We find cancer research is generally not correlated with the relative burden of mutation within the different genetic drivers of cancer.Conclusions: We suggest that cancer research would benefit from incorporating, among other factors, an epidemiologically informed mutation-estimate baseline into a larger framework for funding and research allocation decisions.Funding: This work was supported in part by the National Institutes of Health (NIH) P30CA014195 and NIH DP2AT011327.","PeriodicalId":29964,"journal":{"name":"Med","volume":" ","pages":"832-838.e4"},"PeriodicalIF":12.8000,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2024.05.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cancer research is pursued with the goal of positively impacting patients with cancer. Decisions regarding how to allocate research funds reflect a complex balancing of priorities and factors. Even though these are subjective decisions, they should be made with consideration of all available objective facts. An accurate estimate of the affected cancer patient population by mutation is one variable that has only recently become available to inform funding decisions.

Methods: We compared the overall incident burden of mutations within each cancer-associated gene with two measures of cancer research efforts: research grant funding amounts and numbers of academic manuscripts. We ask to what degree the aggregate set of cancer research efforts reflects the relative burdens of the different cancer genetic drivers. We thoroughly investigate the design of our queries to ensure that the presented results are robust and conclusions are well justified.

Findings: We find cancer research is generally not correlated with the relative burden of mutation within the different genetic drivers of cancer.

Conclusions: We suggest that cancer research would benefit from incorporating, among other factors, an epidemiologically informed mutation-estimate baseline into a larger framework for funding and research allocation decisions.

Funding: This work was supported in part by the National Institutes of Health (NIH) P30CA014195 and NIH DP2AT011327.

查看原文本刊更多论文

癌症研究与驱动基因突变负担无关。

背景：癌症研究的目标是对癌症患者产生积极影响。如何分配研究资金的决定反映了对各种优先事项和因素的复杂平衡。尽管这些都是主观决定，但在做出决定时应考虑到所有可用的客观事实。对受突变影响的癌症患者群体的准确估计是最近才出现的一个变量，可为资金决策提供参考：我们将每个癌症相关基因突变的总体事件负担与癌症研究工作的两个衡量标准进行了比较：研究基金资助金额和学术手稿数量。我们询问癌症研究工作的总体情况在多大程度上反映了不同癌症基因驱动因素的相对负担。我们彻底调查了我们的查询设计，以确保所呈现的结果是可靠的，结论是合理的：我们发现癌症研究通常与不同癌症遗传驱动因素中突变的相对负担无关：我们建议，除其他因素外，将基于流行病学的突变估算基线纳入更大的资助和研究分配决策框架，将对癌症研究大有裨益：这项工作得到了美国国立卫生研究院（NIH）P30CA014195 和 NIH DP2AT011327 的部分支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.